Structural Chemogenomics Group, Laboratoire d'Innovation Thérapeutique, UMR 7200 CNRS-UdS, 74 route du Rhin, 67400 Illkirch, France.
ChemMedChem. 2011 Dec 9;6(12):2159-69. doi: 10.1002/cmdc.201100317. Epub 2011 Oct 12.
Despite the availability of X-ray crystal structure data for several members of the G-protein-coupled receptor (GPCR) superfamily, structure-based discovery of GPCR ligands has been exclusively restricted to class A (rhodopsin-like) receptors. Herein we report the identification, by a docking-based virtual screening approach, of noncompetitive ligands for two related class B (secretin-like) GPCRs: the glucagon receptor (GLR) and the glucagon-like peptide 1 receptor (GLP-1R). Starting from a knowledge-based three-dimensional model of the GLR, a database of 1.9 million commercially available drug-like compounds was screened for chemical similarity to existing GLR noncompetitive antagonists and docked to the transmembrane cavity of the GLR; 23 compounds were then selected based on protein-ligand interaction fingerprints, and were then purchased and evaluated for in vitro binding to GLR and modulation of glucagon-induced cAMP release. Two of the 23 compounds inhibited the effect of glucagon in a dose-dependent manner, with one inhibitor exhibiting the same potency as L-168 049, a reference noncompetitive GLR antagonist, in a whole-cell-based functional assay. Interestingly, one virtual hit that was inactive at the GLR was shown to bind to GLP-1R and potentiate the response to the endogenous GLP-1 ligand.
尽管已有几种 G 蛋白偶联受体 (GPCR) 超家族成员的 X 射线晶体结构数据,但基于结构的 GPCR 配体发现仅局限于 A 类(视紫红质样)受体。在此,我们报告了通过基于对接的虚拟筛选方法鉴定两种相关 B 类(分泌素样)GPCR 的非竞争性配体:胰高血糖素受体 (GLR) 和胰高血糖素样肽 1 受体 (GLP-1R)。从基于知识的 GLR 三维模型开始,对 190 万种商业上可获得的类药物化合物数据库进行了化学相似性筛选,以寻找与现有 GLR 非竞争性拮抗剂的相似性,并对接至 GLR 的跨膜腔;然后根据蛋白-配体相互作用指纹选择了 23 种化合物,然后购买并评估其对 GLR 的体外结合和对胰高血糖素诱导的 cAMP 释放的调节作用。23 种化合物中有两种以剂量依赖的方式抑制了胰高血糖素的作用,其中一种抑制剂在基于全细胞的功能测定中与 L-168049(参考非竞争性 GLR 拮抗剂)具有相同的效力。有趣的是,一种在 GLR 中无活性的虚拟命中物被证明与 GLP-1R 结合并增强对内源性 GLP-1 配体的反应。